Table 2. List of inhibitors and their effects on 7KCh-induced inflammation.

INHIBITOR	Target/Pathway	Conc (µM)	in vivo	VEGF	IL-1β	IL-6	IL-8	CHOP	GRP78	Cell death
MKP2 overexpression	JNK, ERK, p38MAPK	N/A	N/A	↓58%	↓95%	↓75%	↓81%	↓45%	↓59%	None
SP600125	JNK	5	N/A	↔	↔	↑42%	↔	↑25%	↔	ND
UO126 (ERK1/2)	ERK1/2 EGFR	10	N/A	↔	↔	↔	↔	↔	↔	ND
SB203580	p38MAPK	10	N/A	↔	↑64%	↔	↑23%	↔	↔	ND
dnIκBα overexpression	NFκB	N/A	N/A	↓29%	↓83%	↓90%	↓99%	↓45%	↓36%	Protected
LY294002	PI3K, CK2, EGFR, Wnt	10	N/A	↓45%	↓52%	↔	↓36%	↓42%	↓56%	None
Wortmannin	PI3K	1	N/A	↔	↑27%	↑70%	↑48%	↔	↔	ND
P110α siRNA	PI3K	N/A	N/A	↔	↔	↔	↑23%	↑23%	↔	ND
TBB	CK2	5	N/A	↔	↑25%	↑62%	↔	↔	↔	ND
β-catenin siRNA	Wnt	N/A	N/A	↔	↔	↔	↔	↔	↔	ND
AG1478	EGFR	5	no	↓41%	↔	↔	↔	↓52%	↓47%	Protected
NLRP3 siRNA	inflammasome	NA	N/A	↑47%	↔	↔	↔	↔	↔	ND
YVAD-CMK	caspase-1	10	no	↔	↔	↔	↔	↔	↔	ND
CLI-095	TLR4	10	yes	↓62%	↓92%	↓96%	↓98%	↓69%	↓81%	Protected
LPS 50 µg/ml	TLR4	50 µg/ml	yes	↓69%	↓65%	↓30	↓80%	↓88%	↓79%	Protected
ATF4 siRNA	EGFR, ER stress	N/A	N/A	↔	↔	↔	↔	↔	↔	None
CHOP siRNA	EGFR, ER stress	N/A	N/A	↔	↔	↓59%	↔	↓81%	↔	None
TOLLIP overexpression	IRAK4	N/A	N/A	↔	↔	↔	↔	↔	↔	ND
ST2825	MyD88 (TLRs)	10	N/A	↔	↓48%	↓43%	↔	↔	↔	ND
IRAK1/4 inhibitor	IRAK1/4	10	N/A	↔	↓58%	↔	↔	↔	↔	ND
Amlexanox1	IKKε/TBK	10	N/A	↑34%	↔	↑46%	↑35%	↑42%	↑49%	ND
Necrostatin	RIP1	10	N/A	↑38%	↑47%	↑42%	↑32%	↑43%	↑39%	ND
TRAF1 overexpression	TRIF	N/A	N/A	↔	↓63%	↓55%	↓47%	↓24%	↔	ND
BI-D1870	RSK1-4, PLK1	10	yes	↓63%	↓89%	↓75%	↔	↔	↔	Protected
SL0101	RSK1,2	10	N/A	↔	↔	↔	↔	↓21%	↔	Protected
SOCS2 overexpression	multiple	N/A	N/A	↓26%	↓48%	↓37%	↓34%	↓21%	↓18%	ND
SOCS3 overexpression	multiple	N/A	N/A	↔	↓38%	↓40%	↔	↔	↔	ND

This table summarizes all of the measured interactions mentioned in this study.

Definitions: N/A, not applicable, ↔ no statistically significant effect, ↓ down regulation, ↑ up regulation, ND, not determined.